Generic Name and Formulations:
Atropine sulfate 1%; oph soln; contains benzalkonium chloride.
Alcon Laboratories, Inc.
For mydriasis and/or cycloplegia. For cycloplegic refraction, for papillary dilation desired in inflammatory conditions of the iris and uveal tract.
Compress lacrimal sac by digital pressure for 2–3 minutes after instillation to avoid excessive systemic absorption. Uveitis: 1–2 drops in the eye(s) up to 4 times daily. Heavily pigmented irides may require larger doses.
Primary glaucoma or tendency toward glaucoma (eg, narrow anterior chamber angle).
Previous susceptibility to belladonna alkaloids; excessive use may produce systemic symptoms of atropine poisoning. Estimate depth of angle of anterior chamber to avoid inducing angle closure glaucoma. Infants. Pregnancy (Cat.C). Nursing mothers.
Prolonged use: follicular conjunctivitis, vascular congestion, edema, exudate, eczematoid dermatitis; hypotension, progressive respiratory depression (with excessive systemic absorption); children: coma, death possible.
Join MIMS Learning now to manage all your CPD and notes in one place!
Already a MIMS Learning member?Sign In Now »
This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...
This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...
Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...
In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...
This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...
Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...